These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 37496742)

  • 1. Central nervous system-related safety and tolerability of add-on ketamine to standard of care treatment in treatment-resistant psychotic depression in patients with major depressive disorder and bipolar disorder.
    Gałuszko-Wȩgielnik M; Jakuszkowiak-Wojten K; Wiglusz MS; Cubała WJ; Pastuszak M
    Front Neurosci; 2023; 17():1214972. PubMed ID: 37496742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dissociative symptoms with intravenous ketamine in treatment-resistant depression exploratory observational study.
    Włodarczyk A; Cubała WJ; Gałuszko-Węgielnik M; Szarmach J
    Medicine (Baltimore); 2021 Jul; 100(29):e26769. PubMed ID: 34398056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous Ketamine Infusions in Treatment-Resistant Bipolar Depression: An Open-Label Naturalistic Observational Study.
    Wilkowska A; Włodarczyk A; Gałuszko-Węgielnik M; Wiglusz MS; Cubała WJ
    Neuropsychiatr Dis Treat; 2021; 17():2637-2646. PubMed ID: 34421299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Central nervous system-related safety and tolerability of add-on ketamine to antidepressant medication in treatment-resistant depression: focus on the unique safety profile of bipolar depression.
    Włodarczyk A; Cubała WJ; Gałuszko-Węgielnik M; Szarmach J
    Ther Adv Psychopharmacol; 2021; 11():20451253211011021. PubMed ID: 34046159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and Tolerability of the Acute Ketamine Treatment in Treatment-Resistant Depression: Focus on Comorbidities Interplay with Dissociation and Psychomimetic Symptoms.
    Włodarczyk A; Dywel A; Cubała WJ
    Pharmaceuticals (Basel); 2023 Jan; 16(2):. PubMed ID: 37259323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid and longer-term antidepressant effects of repeated-dose intravenous ketamine for patients with unipolar and bipolar depression.
    Zheng W; Zhou YL; Liu WJ; Wang CY; Zhan YN; Li HQ; Chen LJ; Li MD; Ning YP
    J Psychiatr Res; 2018 Nov; 106():61-68. PubMed ID: 30278319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ketamine as Add-On Treatment in Psychotic Treatment-Resistant Depression.
    Gałuszko-Węgielnik M; Chmielewska Z; Jakuszkowiak-Wojten K; Wiglusz MS; Cubała WJ
    Brain Sci; 2023 Jan; 13(1):. PubMed ID: 36672123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A preliminary study of adjunctive ketamine for treatment-resistant bipolar depression.
    Zheng W; Zhou YL; Liu WJ; Wang CY; Zhan YN; Lan XF; Zhang B; Ning YP
    J Affect Disord; 2020 Oct; 275():38-43. PubMed ID: 32658821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A simplified 6-Item clinician administered dissociative symptom scale (CADSS-6) for monitoring dissociative effects of sub-anesthetic ketamine infusions.
    Rodrigues NB; McIntyre RS; Lipsitz O; Lee Y; Cha DS; Shekotikhina M; Vinberg M; Gill H; Subramaniapillai M; Kratiuk K; Lin K; Ho R; Mansur RB; Rosenblat JD
    J Affect Disord; 2021 Mar; 282():160-164. PubMed ID: 33418362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Tolerability of Two Novel "Standard of Care" Treatments-Intranasal Esketamine Versus Intravenous Ketamine-for Treatment-Resistant Depression in Naturalistic Clinical Practice: Protocol for a Pilot Observational Study.
    Gutierrez G; Rosenblat J; Hawken E; Swainson J; Vazquez G
    JMIR Res Protoc; 2022 May; 11(5):e34711. PubMed ID: 35604752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study.
    Hu YD; Xiang YT; Fang JX; Zu S; Sha S; Shi H; Ungvari GS; Correll CU; Chiu HF; Xue Y; Tian TF; Wu AS; Ma X; Wang G
    Psychol Med; 2016 Feb; 46(3):623-35. PubMed ID: 26478208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and tolerability of IV ketamine in adults with major depressive or bipolar disorder: results from the Canadian rapid treatment center of excellence.
    Rodrigues NB; McIntyre RS; Lipsitz O; Lee Y; Cha DS; Nasri F; Gill H; Lui LMW; Subramaniapillai M; Kratiuk K; Lin K; Ho R; Mansur RB; Rosenblat JD
    Expert Opin Drug Saf; 2020 Aug; 19(8):1031-1040. PubMed ID: 32539491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse Events and Measurement of Dissociation After the First Dose of Esketamine in Patients With TRD.
    Williamson D; Turkoz I; Wajs E; Singh JB; Borentain S; Drevets WC
    Int J Neuropsychopharmacol; 2023 Mar; 26(3):198-206. PubMed ID: 36525338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression.
    aan het Rot M; Collins KA; Murrough JW; Perez AM; Reich DL; Charney DS; Mathew SJ
    Biol Psychiatry; 2010 Jan; 67(2):139-45. PubMed ID: 19897179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and Tolerability of Ketamine Use in Treatment-Resistant Bipolar Depression Patients with Regard to Central Nervous System Symptomatology: Literature Review and Analysis.
    Włodarczyk A; Cubała WJ
    Medicina (Kaunas); 2020 Feb; 56(2):. PubMed ID: 32050466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults.
    McCloud TL; Caddy C; Jochim J; Rendell JM; Diamond PR; Shuttleworth C; Brett D; Amit BH; McShane R; Hamadi L; Hawton K; Cipriani A
    Cochrane Database Syst Rev; 2015 Sep; (9):CD011611. PubMed ID: 26415966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, crossover comparison of ketamine and electroconvulsive therapy for treatment of major depressive episodes: a Canadian biomarker integration network in depression (CAN-BIND) study protocol.
    Phillips JL; Jaworska N; Kamler E; Bhat V; Blier J; Foster JA; Hassel S; Ho K; McMurray L; Milev R; Moazamigoudarzi Z; Placenza FM; Richard-Devantoy S; Rotzinger S; Turecki G; Vazquez GH; Kennedy SH; Blier P;
    BMC Psychiatry; 2020 Jun; 20(1):268. PubMed ID: 32487236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder.
    Dean RL; Marquardt T; Hurducas C; Spyridi S; Barnes A; Smith R; Cowen PJ; McShane R; Hawton K; Malhi GS; Geddes J; Cipriani A
    Cochrane Database Syst Rev; 2021 Oct; 10(10):CD011611. PubMed ID: 34623633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between peripheral biomarkers and clinical response to IV ketamine for unipolar treatment-resistant depression: An open label study.
    Kang MJY; Vazquez GH
    J Affect Disord; 2022 Dec; 318():331-337. PubMed ID: 36070831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Relationship Between Acute Dissociative Effects Induced by Ketamine and Treatment Response in Adolescent Patients with Treatment-Resistant Depression.
    Lineham A; Avila-Quintero VJ; Bloch MH; Dwyer J
    J Child Adolesc Psychopharmacol; 2023 Feb; 33(1):20-26. PubMed ID: 36799961
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.